Drug intelligence / Profile preview

PG-110

Development stage: Preclinical
Lead developer: ProGen
Modality: Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

PG-110 is an antibody fusion protein drug candidate developed by ProGen. It is being investigated for the treatment of obesity and other endocrinology and metabolic diseases. As of May 2025, its highest global R&D status is preclinical, with no reported clinical trial data or regulatory approvals. The specific mechanism of action and molecular targets have not been publicly disclosed.

Other names: PG-110PG110PG 110

Beyond the preview

Go deeper on PG-110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PG-110.

Explore the full profile